By Kimberly Chin

SomaLogic Inc.'s shares rose 13% after hours to $11.69 after the company said it has partnered with Illumina Inc., a genomic sequencing and array-based technology company, in an exclusive, multi-year agreement to develop co-exclusive and co-branded next-generation sequencing-based proteomics products.

The partnership will bring together Illumina's global commercial infrastructure with SomaLogic's proteomics platform, bioinformatics tools and a clinical proteomics database, the companies said. The deal's financial terms weren't disclosed.

SomaLogic's SomaScan technology and Illumina's next-generation sequencing, or NGS, platforms could help researchers analyze thousands of samples for more than 10,000 protein targets, the companies said.

SomaLogic's platform can currently run 7,000 protein measurements with a single 55-microliter plasma or serum sample, it said.

"Proteins play a central role in cellular function and health, and NGS can support a greater understanding of this role by unlocking biological insights at scale," Illumina Chief Technology Officer Alex Aravanis said in prepared remarks.

Write to Kimberly Chin at kimberly.chin@wsj.com

(END) Dow Jones Newswires

01-05-22 1717ET